Diligence memo · auto-generated · as of July 2, 2026
Me Biosciences, Inc.
Me Biosciences, Inc. looks fair against its niche peers and is dormant on financing cadence.
Businessfiled
Me Biosciences, Inc. operates in Biotech / Pharma, based in BOULDER.
No verified homepage on file yet — operating evidence is limited to the public record.
Capital & rounds (filed)filed
Me Biosciences, Inc. has raised $1.4M in disclosed capital across 3 recorded rounds, aggregated from public filings. Its latest round is modeled as Pre-Seed (a round under $1.0M).
Largest single filing: $500K on 2018-08-09.
Most recent recorded round closed around 2018-08-09.
Valuation (modeled)modeled
Provath models Me Biosciences, Inc. at approximately $26M (range $273K–$290M). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.
Read: Fair. Modeled value is 1.43× the median modeled value of Pre-Seed Biotech / Pharma companies in 2016–2018 (12 peers) — value vs value, same stage and era. Within the normal band (143% of peer median) for its niche.
Financing rhythm & timingmixed
Historic cadence: a new round about every 17 months.
Last raise 7.9 yr ago; this sector typically re-raises about every 15 months.
Silent for over 3× the sector's normal cadence.
The last round stepped up 1.1× from the prior — scaling.
Comparablesmixed
Capital scale ranks ahead of 32% of Biotech / Pharma peers (227 compared).
Modeled value ranks above 48% of those peers.
Closest niche peers: Orbis Biosciences, Inc, Nexion Biosciences Inc, Synereca Pharmaceuticals, Inc., Novome Biotechnologies, Inc., Continuum Biosciences, Inc..
Peoplefiled
3 named people on file across officers, directors and signatories.
Risks & flagsmixed
Financing has been silent well beyond sector cadence — possibly defunct, acquired, or paused.
No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.